Eyebright Medical Technology Beijing Co Ltd Asset Resilience Ratio
Eyebright Medical Technology Beijing Co Ltd asset resilience ratio. Eyebright Medical Technology Beijing Co Ltd (688050) has an Asset Resilience Ratio of 1.51% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Eyebright Medical Technology Beijing Co to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Eyebright Medical Technology Beijing Co Ltd (2018–2025)
Asset resilience ratio of Eyebright Medical Technology Beijing Co Ltd from 2018 to 2025. This chart shows how Eyebright Medical Technology Beijing Co Ltd's Asset Resilience Ratio has changed over time. Read 688050 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Eyebright Medical Technology Beijing Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Eyebright Medical Technology Beijing Co .
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥72.13 Million | 1.51% |
| Total Liquid Assets | CN¥72.13 Million | 1.51% |
Asset Resilience Insights
- Limited Liquidity: Eyebright Medical Technology Beijing Co Ltd maintains only 1.51% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Eyebright Medical Technology Beijing Co Ltd Industry Peers by Asset Resilience Ratio
Compare Eyebright Medical Technology Beijing Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Imeik Technology Development Co
SHE:300896 |
Medical Instruments & Supplies | 26.02% |
|
SciVision Biotech Inc
TW:1786 |
Medical Instruments & Supplies | 6.42% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 7.53% |
|
Nanosonics Ltd
AU:NAN |
Medical Instruments & Supplies | 46.84% |
|
SDI Ltd
AU:SDI |
Medical Instruments & Supplies | 3.36% |
|
Austco Healthcare Ltd
AU:AHC |
Medical Instruments & Supplies | 15.90% |
|
Trajan Group Holdings Ltd
AU:TRJ |
Medical Instruments & Supplies | 0.29% |
|
Osteopore Ltd
AU:OSX |
Medical Instruments & Supplies | 22.60% |
Eyebright Medical Technology Beijing Co Ltd Asset Resilience Ratio by Year (2018–2025)
Eyebright Medical Technology Beijing Co Ltd asset resilience ratio by year from 2018 to 2025. The table below shows the annual Asset Resilience Ratio data for Eyebright Medical Technology Beijing Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 4.28% | CN¥166.33 Million ≈ $24.34 Million |
CN¥3.89 Billion ≈ $568.92 Million |
+0.50pp |
| 2024-12-31 | 3.78% | CN¥132.27 Million ≈ $19.36 Million |
CN¥3.50 Billion ≈ $511.72 Million |
+3.13pp |
| 2023-12-31 | 0.66% | CN¥20.12 Million ≈ $2.94 Million |
CN¥3.06 Billion ≈ $448.04 Million |
-20.82pp |
| 2022-12-31 | 21.47% | CN¥481.97 Million ≈ $70.53 Million |
CN¥2.24 Billion ≈ $328.43 Million |
+21.45pp |
| 2021-12-31 | 0.02% | CN¥478.90K ≈ $70.08K |
CN¥2.05 Billion ≈ $299.63 Million |
+0.01pp |
| 2020-12-31 | 0.02% | CN¥278.08K ≈ $40.69K |
CN¥1.64 Billion ≈ $239.77 Million |
-0.44pp |
| 2018-12-31 | 0.45% | CN¥2.65 Million ≈ $388.39K |
CN¥586.45 Million ≈ $85.82 Million |
-- |
About Eyebright Medical Technology Beijing Co Ltd
Eyebright Medical Technology (Beijing) Co., Ltd. engages in development, production, and commercialization of ophthalmic medical devices in China and internationally. The company offers intraocular, trimmers, capsular tension ring, defocus lense, orthokeratology, and contact lenses in the areas of surgical treatment, myopia management, and consumer vision care. It also provides solutions for opht… Read more